This activity was originally presented at the 2026 HOPA Annual Conference in New Orleans, LA.
Gastroesophageal adenocarcinoma (GEA) represents a significant global health burden, with esophageal cancer ranking as the seventh leading cause of cancer death worldwide and gastric cancer contributing substantially to mortality. Despite advances in multimodal treatment approaches, the median overall survival for patients with advanced GEA remains poor. Precision medicine approaches with biomarker-driven targeted therapies and immunotherapy in first-line treatment paradigms for advanced GEA are promising. Yet, the complex biomarker landscape in GEA requires oncology pharmacists to be well-versed in comprehensive testing to ensure optimal treatment selection and maximize identification of patients eligible for targeted therapies. This session will equip oncology pharmacists with the knowledge and skills needed to optimize outcomes for patients with advanced GEA through comprehensive biomarker testing workflows, particularly for the integration of HER2- and CLDN18.2-targeted therapies. The program will explore the epidemiology and pathobiology of key biomarkers in GEA, review FDA-approved diagnostic assays and interpretation nuances, and establish best-practice testing workflows that minimize turnaround time and ensure results are available before first-line treatment decisions. Interactive case discussions will illustrate real-world application of biomarker testing workflows and treatment decision-making in patients with HER2-positive and HER2-negative/CLDN18.2-positive GEA, emphasizing operational safeguards, patient-specific factors influencing treatment selection, and pharmacist-led interventions to proactively implement toxicity management strategies.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 15, 2026
Expiration date: April 15, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Employ best-practice frameworks for biomarker testing workflows in advanced gastroesophageal adenocarcinoma (GEA) to support timely identification of patients eligible for targeted therapies
- Manage the use of HER2- and CLDN18.2-targeted therapies in treatment planning for advanced GEA based on pivotal evidence, biomarker profiles, and patient-specific factors
- Construct evidence-based strategies to prevent, monitor, and manage toxicities associated with HER2- and CLDN18.2-directed therapeutic regimens in advanced GEA
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here